Patents by Inventor Kevin B. Gurney

Kevin B. Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY CELL-BASED POTENCY ASSAY
    Publication number: 20230399648
    Abstract: The disclosure describes methods for measuring the potency of anti-Respiratory Syncytial Virus (RSV) antibody against respiratory syncytial virus in a cell culture system using an RSV reporter virus. The disclosure also describes respiratory syncytial viruses that carry a reporter gene, and expression vectors for producing an infectious recombinant respiratory syncytial virus (RSV) that carry a reporter gene.
    Type: Application
    Filed: November 8, 2021
    Publication date: December 14, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Dai WANG, John P. BILELLO, Kevin B. GURNEY, Ping HAN, Xi HE, Dengyun SUN, Amy Hsu TOU
  • LAG3 ANTAGONIST CELL BASED POTENCY ASSAY
    Publication number: 20230333090
    Abstract: The present disclosure describes a murine T cell 3A9 comprising a polynucleotide sequence encoding human LAG3, and a murine IL-2 promotor operably associated with a reporter gene. The disclosure also describes a cell-based potency assay for measuring LAG3 antagonist activity using a co-cultured system with the murine T cells and LK35.2 murine B cells, and hen egg lysozyme peptide.
    Type: Application
    Filed: December 16, 2020
    Publication date: October 19, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kevin B. Gurney, Yue Zhang, Linda Liang, Cuiwei Ai
  • A VIRUS NEUTRALIZATION ASSAY UTILIZING IMAGING CYTOMETRY
    Publication number: 20210293818
    Abstract: The instant invention describes a virus reduction neutralization test (VRNT) which is a rapid, high throughput alternative to current standard low throughput and laborious neutralization assays. The VRNT utilizes imaging cytometry to count virus-infected cells at about one day post-infection (thus eliminating the wait time other assays employ allowing for viral infection cell to cell), reducing overall assay time and increasing throughput at least 15-fold.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Melissa C. Whiteman, Joseph M. Antonello, Leah A. Bogardus, Danila G. Giacone, Dengyun Sun, Amy H.M. Tou, Kevin B. Gurney, Leonard J. Rubinstein